Servier Completes Acquisition of Day One Biopharmaceuticals
Servier has completed its acquisition of Day One Biopharmaceuticals for $21.50 per share, valued at approximately $2.5 billion in total equity. The deal expands Servier's oncology portfolio with the FDA-approved drug OJEMDATM (tovorafenib) and a pipeline targeting rare cancers. The acquisition strengthens Servier's leadership in pediatric low-grade glioma and supports its 2030 ambition in rare cancers.
Tickers: $DAWN
Topics: acquisition oncology pharmaceutical industry pipeline development rare cancers